Pharma-Bio Serv (PBSV) Cash & Equivalents (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Cash & Equivalents for 17 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 14.41% year-over-year to $1.8 million; the trailing twelve-month figure through Apr 2026 stood at $1.8 million (down 14.41% YoY), and the FY2025 full-year result was $3.4 million, down 50.07% from the prior year.
• Cash & Equivalents eased to $1.8 million in Q2 2026 per PBSV's latest filing, from $5.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $15.4 million in Q1 2022 and bottomed at $1.8 million in Q2 2026.
• Historically, Cash & Equivalents has averaged $7.4 million across 5 years, with a median of $6.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 79.85% in 2023, then soared 127.22% in 2024.
• Over 5 years, Cash & Equivalents stood at $14.5 million in 2022, then fell by 27.77% to $10.4 million in 2023, then tumbled by 35.22% to $6.8 million in 2024, then tumbled by 50.07% to $3.4 million in 2025, then plunged by 46.99% to $1.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.8 million, $5.8 million, and $3.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.